DXCM vs. SNN: DexCom vs. Smith & Nephew Stock Comparison

Company Profile

DexCom (DXCM) and Smith & Nephew (SNN) are both classified in the Health Care Equipment sub-industry within the broader Health Care Equipment & Supplies industry, placing them in the closest GICS peer bucket.

DexCom (DXCM) trades as ordinary local shares, while Smith & Nephew (SNN) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

DexCom (DXCM) has an aggressive beta of 1.43, indicating higher sensitivity to broad-market moves, while Smith & Nephew (SNN) is defensive at 0.49 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

DexCom (DXCM) at 37.67% sits in the top ROE quartile, while Smith & Nephew (SNN) at 11.85% is closer to the peer norm — stronger capital efficiency for DXCM.

For every dollar of sales, both DexCom (DXCM) at 19.42% and Smith & Nephew (SNN) at 10.08% retain more as net profit than most peers, landing in the top net margin quartile of their industries.

Both DexCom (DXCM) at 24.34% and Smith & Nephew (SNN) at 14.47% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both DexCom (DXCM) at 15.60% and Smith & Nephew (SNN) at 6.09% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Both DexCom (DXCM) at 47.18% and Smith & Nephew (SNN) at 52.34% sit in the top peer quartile for EPS growth, so each is compounding per-share earnings faster than typical industry peers.

Growth Metrics

Financial Strength

Both DexCom (DXCM) at 1.74 and Smith & Nephew (SNN) at 2.14 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

Both DexCom (DXCM) at 0.55 and Smith & Nephew (SNN) at 0.73 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

DexCom (DXCM) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Smith & Nephew (SNN) reports a yield of 1.24%, ranking against industry peers normally.

DexCom (DXCM) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Smith & Nephew (SNN) reports a payout of 53.20%, ranking against industry peers normally.

Dividend Metrics

Valuation

Both DexCom (DXCM) at 31.26 and Smith & Nephew (SNN) at 21.19 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

Smith & Nephew (SNN) at 2.07 is priced about in line with its industry on P/S ratio, while DexCom (DXCM) at 5.80 sits in the pricier quartile — DXCM costs more per dollar of sales.

Both look rich against book: DexCom (DXCM) at 11.68 sits in the upper P/B ratio quartile, and Smith & Nephew (SNN) at 12.80 prices even higher, above its industry range.

Valuation Metrics